HIGHLIGHTS
- What: Our analysis suggests that while both adalimumab and secukinumab are effective in reducing hidradenitis suppurativa disease activity, adalimumab did so by almost 15% more than the biweekly-treated secukinumab group.
- Who: Sultan Akbar from the ATStill University, School of Osteopathic Medicine in Arizona (ATSU-SOMA). have published the article: Pharmacotherapy of Hidradenitis Suppurativa: A Comparison of Clinical Response with Adalimumab and Secukinumab, in the Journal: (JOURNAL)
- Future: Studies with greater sample sizes are needed to conclude which has greater efficacy.
SUMMARY
There is sufficient information to suggest that . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.